rs114368325
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM5PP3PP5_Very_Strong
The NM_000782.5(CYP24A1):โc.1186C>Tโ(p.Arg396Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000778 in 1,614,010 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (โ โ ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R396Q) has been classified as Pathogenic.
Frequency
Consequence
NM_000782.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP24A1 | NM_000782.5 | c.1186C>T | p.Arg396Trp | missense_variant | 9/12 | ENST00000216862.8 | NP_000773.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP24A1 | ENST00000216862.8 | c.1186C>T | p.Arg396Trp | missense_variant | 9/12 | 1 | NM_000782.5 | ENSP00000216862 | P1 | |
CYP24A1 | ENST00000395955.7 | c.1186C>T | p.Arg396Trp | missense_variant | 9/11 | 1 | ENSP00000379285 | |||
CYP24A1 | ENST00000395954.3 | c.760C>T | p.Arg254Trp | missense_variant | 7/10 | 1 | ENSP00000379284 |
Frequencies
GnomAD3 genomes AF: 0.000775 AC: 118AN: 152206Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000665 AC: 167AN: 251228Hom.: 1 AF XY: 0.000655 AC XY: 89AN XY: 135800
GnomAD4 exome AF: 0.000779 AC: 1138AN: 1461686Hom.: 3 Cov.: 32 AF XY: 0.000799 AC XY: 581AN XY: 727158
GnomAD4 genome AF: 0.000775 AC: 118AN: 152324Hom.: 0 Cov.: 33 AF XY: 0.000618 AC XY: 46AN XY: 74482
ClinVar
Submissions by phenotype
Hypercalcemia, infantile, 1 Pathogenic:9
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 23, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 20, 2017 | The CYP24A1 c.1186C>T (p.Arg396Trp) variant has been reported in seven studies and identified in a total of ten individuals with infantile hypercalcemia including three homozygotes and seven compound heterozygotes, two of which are siblings (Schlingmann et al. 2011; Fencl et al. 2013; Skalova et al. 2013; Dinour et al. 2015; Cools et al. 2015; Shah et al. 2015; Figueres et al. 2015). The p.Arg396Trp variant was identified in four of 1024 control alleles and is reported at a frequency of 0.001482 in the European (Finnish) population of the Genome Aggregation Database. Schlingmann et al. (2011) performed functional studies using transiently transfected V79-4 cells and observed a complete loss of enzyme activity in cells with the variant protein as compared to wild type. Based on the collective evidence, the p.Arg396Trp variant is classified as pathogenic for infantile hypercalcemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU Mรผnchen | Sep 21, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 03, 2011 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Jan 05, 2024 | This sequence change in CYP24A1 is predicted to replace arginine with tryptophan at codon 396, p.(Arg396Trp). The arginine residue is highly conserved (100 vertebrates, UCSC). There is a large physicochemical difference between arginine and tryptophan. The highest population minor allele frequency in the population database gnomAD v2.1 is 0.1% (148/129,106 alleles) in the European non-Finnish population. This variant has been reported in multiple individuals with idiopathic infantile hypercalcaemia in the homozygous or compound heterozygous state (PMID: 21675912, 24518185, 23001465, 36703897, 34858904, 37701149). An in vitro functional assay with limited validation demonstrated the variant leads to a complete loss of enzyme activity (PMID: 21675912). A knock-in mouse model for the variant demonstrated a decrease in vitamin D levels and an increase in calcium levels indicating that this variant impacts protein function due to its reduced enzyme activity (PMID: 21675912, 35956396). Computational evidence predicts a deleterious effect for the missense substitution (REVEL = 0.873). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.6.1, this variant is classified as PATHOGENIC. Following criteria are met: PM3_VeryStrong, PP3, PS3_Moderate - |
Pathogenic, no assertion criteria provided | clinical testing | Molecular Genetics Laboratory, Biocruces Bizkaia Health Research Institute | Mar 08, 2024 | - - |
Pathogenic, no assertion criteria provided | research | Division of Human Genetics, Children's Hospital of Philadelphia | May 05, 2015 | This patient is a carrier of a heterozygous pathogenic variant in the CYP24A1 gene implicated in causing autosomal recessive infantile hypercalcemia (MIM 143880). The CYP24A1 variant (c.1186C>T) was identified in several patients in both the homozygous and compound heterozygous state (Schlingmann et al. 2011, PMID: 21675912; Fencl et al. 2013, PMID: 23001465; Wolf et al. 2014, PMID: 24518185). Functional studies of this variant showed an inability of the protein to metabolize 1,25-dihydroxyvitamin D3 (Schlingmann et al. 2011, PMID: 21675912). - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Mar 20, 2024 | PS3, PM3_Strong, PM5, PP3 - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 17, 2021 | - - |
not provided Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 20, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 29, 2024 | Published functional studies demonstrate this variant results in the loss of enzymatic activity (PMID: 21675912); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26097993, 36703897, 37701149, 23485543, 34337279, 34805638, 34320495, 34515170, 32743688, 23001465, 24518185, 22047571, 25194629, 21675912, 26117226, 28324001, 30729229, 29786188, 27798933, 31751313, 3490596, 25446019, 27394135, 31672324, 31980526, 26585929, 34307984, 34426522, 31589614, 33099630, 33186763, 33226606, 33502802, 33726816, 35569070, 28470390) - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Feb 07, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 396 of the CYP24A1 protein (p.Arg396Trp). This variant is present in population databases (rs114368325, gnomAD 0.1%), including at least one homozygous and/or hemizygous individual. This missense change has been observed in individuals with idiopathic infantile hypercalcemia (PMID: 21675912, 23001465, 23485543, 25446019, 27394135, 27798933, 28470390). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 29679). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CYP24A1 protein function. Experimental studies have shown that this missense change affects CYP24A1 function (PMID: 21675912). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostics Lab, Nemours Children's Health, Delaware | Oct 17, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2024 | CYP24A1: PM3:Very Strong, PM5, PM2:Supporting - |
Muscle spasm Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jul 01, 2015 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at